

## **Product datasheet for TR313494**

## **OriGene Technologies, Inc.**9620 Medical Center Drive, Ste 200

Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

## **DGCR2 Human shRNA Plasmid Kit (Locus ID 9993)**

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** DGCR2 Human shRNA Plasmid Kit (Locus ID 9993)

**Locus ID:** 9993

**Synonyms:** DGS-C; IDD; LAN; SEZ-12

Vector: pRS (TR20003)

E. coli Selection: Ampicillin

Mammalian Cell Puromycin

Selection:

Format: Retroviral plasmids

Components: DGCR2 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID =

9993). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

**RefSeq:** <u>NM 001173533</u>, <u>NM 001173534</u>, <u>NM 001184781</u>, <u>NM 005137</u>, <u>NR 033674</u>, <u>NM 005137.2</u>,

NM 001173534.1, NM 001173533.1, NM 001184781.1, BC040500, BC040500.1, BC020339,

BC032430, BC035425, NM 001184781.2, NM 001173534.2, NM 005137.3

UniProt ID: P98153

**Summary:** Deletions of the 22q11.2 have been associated with a wide range of developmental defects

(notably DiGeorge syndrome, velocardiofacial syndrome, conotruncal anomaly face

syndrome and isolated conotruncal cardiac defects) classified under the acronym CATCH 22. The DGCR2 gene encodes a novel putative adhesion receptor protein, which could play a role in neural crest cells migration, a process which has been proposed to be altered in DiGeorge syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May

2010]

**shRNA Design:** These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).